{"filings":[{"id":1664518,"accession_number":"0001493152-26-033358","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-07-15T20:10:42+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra reports ATR-COSF ex vivo results: 4.4-fold elasticity increase, improved distribution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATR-COSF supernatant with recombinant filaggrin showed increased penetration into stratum granulosum with multiple doses in ex vivo human skin.","Hydrogel with 7.5% w/w supernatant increased skin elasticity 4.4-fold; 0.28% w/w restored elasticity to healthy skin levels.","Safety testing confirmed 2% supernatant formulation is non-irritating and non-corrosive to skin and eyes.","CEO plans to optimize formulations and initiate human study for visible wrinkle reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1093560,"accession_number":"0001493152-26-028994","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-06-17T12:05:40+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra CEO details strategic pivot to cosmetic ingredients and recombinant proteins; pauses Netherton trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $10.5M in March with up to $21M additional from warrant exercises to fund new initiatives.","Launches ATR-COSF, a recombinant filaggrin cosmetic ingredient; expects clinical study completion in late 2026.","In-licenses FHCC minicircle plasmids showing 100,000x improvement; targets TEV protease and T7 RNA Polymerase market (~$1B).","ATR-04 (EGFR inhibitor rash) continues enrollment with MD Anderson as new clinical site.","Pauses ATR-12 Netherton trial enrollment to redirect capital to ATR-COSF near-term milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066239,"accession_number":"0001493152-26-028814","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-06-16T12:00:45+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Azitra shareholders approve authorized share increase from 200M to 750M; reverse split authorized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 200M to 750M; Certificate of Amendment filed June 15, 2026.","Stockholders authorized a reverse stock split (ratio to be set by Board).","Ratified Grassi & Co. as independent auditor for fiscal year ending Dec 31, 2026.","Approved issuance of >19.99% of shares under two securities purchase agreements (Nov 2025 with Alumni Capital; Mar 2026).","Proposal to increase share reserve for 2023 Stock Incentive Plan did not pass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861076,"accession_number":"0001493152-26-027270","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-06-04T20:10:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra adjourns 2026 annual meeting; only 17% of shares voted, needs 33.3% quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Meeting reconvened to June 15, 2026 at 11:00 a.m. ET; record date remains April 24, 2026.","Proxies received represented approx. 17% of outstanding shares; quorum requires 33⅓%.","No changes to proposals; stockholders can vote by mail, Internet, or phone until June 15 at 10:59 a.m. ET.","Company is a clinical-stage biopharma focused on precision dermatology; lead program ATR-12 for Netherton syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":696517,"accession_number":"0001493152-26-025426","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-05-27T20:30:44+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra adjourns 2026 annual meeting to June 15 due to mailing delay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Meeting originally scheduled June 4, 2026; adjourned to June 15, 2026 at 11:00 a.m. ET.","Reason: minor administrative delay in mailing proxy materials to stockholders.","Record date remains April 24, 2026; no changes to proposals or voting procedures.","Stockholders who already voted need not take action; new votes due by June 15 at 10:59 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49441,"accession_number":"0001701478-26-000029","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-05-13T00:09:52+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.","Added MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated rash.","Launched cosmeceutical initiative using filaggrin protein/peptide technologies for fine lines and wrinkles.","Secured new U.S. patent for ATR-12 (Netherton syndrome); Phase 1b topline data expected H2 2026.","Private placement financing of up to ~$10.5M (up to ~$20.9M if warrants exercised)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107445,"accession_number":"0001493152-26-012084","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Azitra raises $10.5M initial PIPE, up to $31.4M with warrants, for cosmetic protein program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial gross proceeds of ~$10.5M from sale of Series A preferred & warrants; potential additional ~$20.9M if warrants exercised.","Warrants exercisable at $0.123/share; Series B warrants expire 18 months after stockholder approval; Series C upon data announcement.","Proceeds to fund R&D for filaggrin protein/peptide cosmetic program targeting $2.3B market growing to $3.7B by 2030.","Insiders including CEO participated; Stonepine Capital and Nantahala Capital among investors.","Company must seek stockholder approval for conversion of preferred shares into common; registration rights agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107444,"accession_number":"0001493152-26-010108","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Azitra receives second NYSE American non-compliance notice; equity at $3.8M vs $6M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American notified Azitra of non-compliance with Section 1003(a)(iii) requiring $6M+ equity; as of Dec 31, 2025 equity was $3.8M.","Company has until April 1, 2027 to regain compliance with both Section 1003(a)(ii) and (iii) under a previously accepted plan.","Audit opinion for 2025 includes a going concern paragraph, disclosed in 10-K filed Feb 27, 2026.","Azitra is assessing funding avenues; failure to meet compliance could lead to delisting proceedings.","No immediate effect on trading; company continues to trade on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107443,"accession_number":"0001493152-26-009003","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra cancels special meeting of stockholders after failing to secure quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting scheduled for Feb 6, 2026 adjourned due to lack of quorum; March 6 reconvening canceled.","Company withdrew all proposals from Jan 2, 2026 proxy statement; no reason provided.","No new meeting date announced; shareholder approval for prior proposals remains in limbo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107442,"accession_number":"0001701478-26-000014","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra reports FY2025 net loss of $11.0M, cash $2.1M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $11.0M in FY2025 from $9.0M in FY2024; R&D $4.8M, G&A $6.2M.","Cash and equivalents of $2.1M as of Dec 31, 2025; completed $8.5M in financings during the year.","First patient dosed in Phase 1/2 trial for ATR-04 (EGFRi rash); Fast Track from FDA.","Topline data expected H2 2026 for ATR-12 (Netherton syndrome) and mid-2026 for ATR-04.","Positive preclinical data for ATR-01 (ichthyosis vulgaris); IND-enabling studies continue in 2026."],"consensus_eps_estimate":-0.3315,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107441,"accession_number":"0001493152-26-005564","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra adjourns special meeting on stock issuance due to lack of quorum; reconvenes March 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting convened Feb 6, 2026, adjourned to March 6, 2026 after only ~13% of shares voted vs. required 33 1/3% quorum.","Meeting is to approve issuance of more than 19.99% of outstanding common stock under Nov 24, 2025 purchase agreement with Alumni Capital LP.","Record date remains Jan 2, 2026; proposals unchanged from prior proxy statement.","Company urges stockholders to vote by 10:59 a.m. ET on March 6, 2026 via proxy or at reconvened virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123787,"accession_number":"0001493152-25-028148","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Azitra obtains NYSE American plan approval; must meet $4M equity by April 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American accepted Azitra's plan to regain compliance with minimum $4M stockholders' equity requirement.","Company has until April 1, 2027 to achieve compliance; quarterly updates required.","Azitra is exploring multiple funding avenues to meet the equity standard.","If not compliant by deadline or progress insufficient, delisting proceedings may be initiated.","The notice does not affect immediate listing or trading of AZTR common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123786,"accession_number":"0001493152-25-025001","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Azitra raises $1.5M in private placement of common stock and warrants at $0.32/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $1.5M from sale of 4,687,500 shares (or pre-funded warrants) and warrants to buy 4,687,500 shares at $0.32.","Common warrants exercisable at $0.32 per share upon shareholder approval, expire 5 years later.","Maxim Group LLC acted as sole placement agent; cash fee 7% of gross proceeds plus 187,500 placement agent warrants.","Proceeds to be used for general corporate purposes; closing occurred November 25, 2025.","Company agreed to file resale registration statement for the securities within 20 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123785,"accession_number":"0001701478-25-000051","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q3 net loss widens to $2.8M; cash $1.4M; first patient dosed in ATR-04 Ph1/2 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.8M for Q3 2025, compared to $1.0M in Q3 2024.","Cash and equivalents $1.4M as of Sept 30, 2025; raised $2.8M gross via equity line from Alumni Capital.","Dosed first patient in Phase 1/2 trial for ATR-04 targeting EGFRi-associated rash; FDA Fast Track granted.","Presented positive preclinical data for ATR-01 (ichthyosis vulgaris) at BIO-Europe.","R&D expenses $1.2M (up from $1.0M), G&A $1.6M (down from $1.9M) YoY."],"consensus_eps_estimate":-0.7905,"consensus_eps_actual":-3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123784,"accession_number":"0001493152-25-016887","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Azitra receives NYSE American delisting notice for insufficient stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $2.2M as of June 30, 2025, below the $4M minimum required.","Company has until October 31, 2025 to submit a plan to regain compliance.","Must regain full compliance by April 1, 2027 or face delisting proceedings.","No immediate impact on trading; company exploring multiple funding avenues.","Failure to submit or execute acceptable plan could lead to delisting from NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140467,"accession_number":"0001493152-25-012476","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Azitra modifies equity line with Alumni Capital; new pricing at 90% or 97% discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modification Agreement dated Aug 26, 2025 amends $20M purchase agreement from April 24, 2025.","Company can now elect Option 1 (90% of lowest daily VWAP over up to 5 business days) or Option 2 (97% of lowest same-day price).","Per-purchase limits unchanged: up to $750,000 (or $4M by mutual agreement); total commitment remains $20M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140466,"accession_number":"0001493152-25-012191","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Azitra announces 1-for-6.66 reverse stock split effective August 21, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:6.66 ratio effective August 21, 2025 at 12:01 a.m. Eastern.","No fractional shares; cash in lieu based on five-day average closing price prior to split.","Stockholders approved split authority at special meeting on February 20, 2025.","CUSIP for post-split common stock will be 05479L 302."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140465,"accession_number":"0001701478-25-000041","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q2 net loss $2.9M; cash $1.0M; ATR-12 Phase 1b shows safety","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.9M for Q2 2025, up from $2.6M in Q2 2024; R&D spend $1.4M, G&A $1.5M.","Cash and equivalents $1.0M as of June 30, 2025; entered $20M equity line with Alumni Capital LP.","ATR-12 Phase 1b in Netherton syndrome: 50% enrolled, promising safety in first 5 patients.","ATR-04 Phase 1/2 for EGFRi rash: design presented at ASCO; first patient dosing expected Q3 2025.","Anticipated topline data for ATR-12 in Q1 2026."],"consensus_eps_estimate":-1.4266,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140464,"accession_number":"0001641172-25-017786","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.03","5.07"],"status":"ready","headline":"Azitra stockholders approve doubling authorized common stock to 200M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment increased authorized common shares from 100M to 200M, effective July 3, 2025.","Approved at reconvened annual meeting with 1,090,701 votes for, 278,960 against, 2,607 abstentions.","Broker non-votes totaled 7,217,442; quorum was met with over one-third of outstanding shares.","Certificate of Amendment filed with Delaware Secretary of State on July 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158153,"accession_number":"0001641172-25-016073","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azitra annual meeting elects directors, approves >19.99% share issuance, adjourns charter vote to July 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four directors elected: Salva, Whitfill, Ryan, Schroer; votes ranged 1.1M-1.26M for, 100K-255K withheld.","Ratification of Grassi & Co. as auditor approved with 8.37M for, 151K against.","Share issuance to Alumni Capital LP exceeding 19.99% of outstanding approved (1.20M for, 155K against).","Charter amendment to increase authorized shares from 100M to 200M not voted; adjourned to July 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158152,"accession_number":"0001641172-25-015636","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azitra updates voting standard for share increase proposal to majority of votes cast","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voting standard for Proposal 2 (increase authorized shares from 100M to 200M) changed to majority of votes cast, per DGCL amendment.","Proposal 2 seeks to amend certificate of incorporation to double authorized common shares to 200M.","Annual Meeting to be held June 23, 2025; board recommends FOR all proposals.","Previously submitted proxies remain valid; no action needed unless change vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158151,"accession_number":"0001641172-25-015342","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Azitra reports Phase 1b safety data for ATR12-351 in Netherton syndrome; no severe adverse events, 50% enrolled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No severe or serious adverse events in ongoing Phase 1b trial of ATR12-351; application site reactions transient, self-resolving, observed bilaterally.","Trial 50% enrolled; six patients dosed with ATR12-351 (engineered S. epidermidis strain delivering LEKTI protein).","Drug candidate generally safe and well-tolerated with occasional mild to moderate local symptoms (itch, redness, burning).","Azitra presenting at 2025 BIO International Convention on June 17, 2025 (12:00PM ET in Boston)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158150,"accession_number":"0001641172-25-009996","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q1 net loss $3.1M, cash $3.2M; secures up to $20M funding from Alumni Capital","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.1M for Q1 2025 vs $2.9M in Q1 2024; R&D $1.3M, G&A $1.9M.","Cash $3.2M as of March 31, 2025; signed up to $20M purchase agreement with Alumni Capital LP.","Closed two public offerings raising $2.2M.","ATR-12 Phase 1b initial safety data expected 1H 2025; topline data by YE 2025.","ATR-04 Phase 1/2 first patient dosing expected 1H 2025; ASCO poster accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158149,"accession_number":"0001641172-25-008331","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Azitra sets 2025 Annual Meeting for June 23; proxy deadlines announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Meeting to be held virtually on June 23, 2025 at 11:00 a.m. ET; record date May 28, 2025.","Stockholder proposals under Rule 14a-8 must be received by May 15, 2025.","Director nominations and other business outside Rule 14a-8 must be submitted by May 12, 2025.","Universal proxy rule compliance notice also due by May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158148,"accession_number":"0001641172-25-006043","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Azitra enters up to $20M equity line with Alumni Capital for clinical pipeline funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase Agreement with Alumni Capital LP for up to $20M of common stock and warrants over 20 months.","Azitra controls timing/amount of sales; purchase price at 90% of lowest VWAP during pricing period.","Each purchase includes warrants for 10% of shares at 130% of purchase price, exercisable for 5 years subject to shareholder approval.","Company must register resale of shares within 60 days; issuance exempt under Section 4(a)(2).","Proceeds to advance pipeline for Netherton Syndrome and EGFRi-associated rash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176517,"accession_number":"0001493152-25-007980","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra reports FY2024 net loss of $9.0M; cash $4.6M; trial updates for ATR-12 and ATR-04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.0M vs $11.3M in FY2023; R&D expenses $4.7M, G&A $6.3M.","Cash $4.6M at Dec 31, 2024; additional $2.2M raised in Jan/Feb 2025.","Phase 1b trial of ATR-12 in Netherton syndrome ongoing; initial safety data expected H1 2025, topline by year-end.","FDA cleared IND and granted Fast Track for ATR-04 for EGFRi rash; multicenter Phase 1/2 to start H1 2025.","Closed $10M and $5M public offerings in 2024; IP portfolio strengthened."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176516,"accession_number":"0001493152-25-007717","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azitra stockholders approve reverse stock split; ratio range 1:2 to 1:7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at ratio from 1:2 to 1:7; board to decide exact ratio and timing.","Votes: 2,435,494 for, 657,144 against, 342 abstentions; no broker non-votes.","Adjournment proposal also passed (2,476,620 for, 614,341 against) but not used.","Special meeting held February 20, 2025; quorum was over one-third of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176515,"accession_number":"0001493152-25-005106","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Azitra closes reduced $695K offering, issues warrants for 90% more shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering reduced from $929,995 to $695,002 to comply with NYSE American rules; 2,495,518 shares sold.","Investors receive warrants to purchase up to 2,245,967 shares (90% of shares purchased), exercisable after 6 months + 1 day, 5-year term.","Warrant exercise price set at greater of book value or market value per NYSE American rules.","Company grants investors a 2-year right to participate in future financings up to 12.5% of each offering.","Warrants and underlying shares are unregistered, issued under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176514,"accession_number":"0001493152-25-005103","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Azitra closes $695K registered direct offering of 2.5M shares at $0.2785/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,495,518 shares of common stock at $0.2785/share for gross proceeds of ~$695,001.","Offering closed on February 6, 2025; Maxim Group LLC acted as sole placement agent.","Placement agent fee of 7.0% of gross proceeds; company also reimburses expenses.","Net proceeds will be used for working capital and general corporate purposes.","Issuer also announced initial pricing of $930K offering on Feb 4, but final terms reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176513,"accession_number":"0001493152-25-002537","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Azitra prices $1.5M public offering of 4.86M shares at $0.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.5M from sale of 4,857,780 shares at $0.30/share; offering closed Jan 16, 2025.","Maxim Group LLC acted as sole placement agent; cash fee of 7% of gross proceeds.","Placement agent warrants for 194,311 shares at $0.375/share (125% of offering price).","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193367,"accession_number":"0001493152-24-047796","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azitra shareholders elect all four director nominees, approve stock plan amendments and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Francisco D. Salva, Travis Whitfill, Barbara Ryan, John Schroer elected with For votes ranging 833,171 to 850,311.","Amendment to 2023 Stock Incentive Plan to reserve additional 1,144,401 shares approved: 663,277 For, 291,773 Against.","Evergreen provision for automatic annual share increases over 10 years approved: 751,718 For, 191,413 Against.","Ratification of Grassi & Co. as independent auditor for FY2024 passed: 2,921,438 For, 111,636 Against, 54,476 Abstain.","All proposals received broker non-votes except auditor ratification; meeting held November 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193366,"accession_number":"0001493152-24-044930","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q3 net loss narrows to $1.0M; pipeline advances with ATR-12 dosing, ATR-04 IND clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.0M in Q3 2024 vs $1.9M in Q3 2023; cash and equivalents $7.3M as of Sept 30, 2024.","R&D expenses rose to $1.0M from $0.5M; G&A steady at $1.9M; service revenue was $0 vs $310K.","Completed $10M follow-on offering; dosed first Netherton syndrome patient with ATR-12 in Phase 1b trial.","Received IND clearance and Fast Track designation from FDA for ATR-04 to treat EGFRi-associated rash.","Anticipates initial safety data from ATR-12 trial in Q1 2025; first ATR-04 patient dosed in Q1 2025; topline data YE 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209713,"accession_number":"0001493152-24-031356","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q2 net loss narrows to $2.6M; completes $10M offering, pipeline milestones set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M improved from $5.1M in Q2 2023; cash and equivalents $0.8M as of June 30.","Completed $10M follow-on offering, expected to fund operations into 2025.","R&D expenses $1.1M (up from $0.8M); G&A $1.5M (up from $0.8M); service revenue $7,500 (down from $172k).","Expects to dose first Netherton syndrome patient with ATR-12 in Q3 2024; plans IND for ATR-04 for EGFRi rash.","Anticipates initial safety data from ATR-12 Phase 1b by year-end 2024, topline data by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209712,"accession_number":"0001493152-24-029228","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Azitra closes $10M public offering of 6.67M shares and warrants at $1.50/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10.0M; net proceeds ~$8.95M after placement agent fees and expenses.","Offering: 6,665,000 common shares plus Class A warrants for 13.33M shares, priced at $1.50 per unit.","Class A warrants exercisable at $1.50/share, subject to reset to as low as $0.32 on Aug 24, 2024.","Maxim Group LLC acted as placement agent, receiving 7% cash fee and warrants for 266,600 shares at $1.875."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209711,"accession_number":"0001493152-24-026211","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Azitra stockholders approve 1-for-30 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1:30; filed with Delaware Secretary of State on June 27, 2024.","Stockholders voted 15,170,007 for, 1,848,647 against, 149,754 abstain.","Board determined exact ratio within previously authorized range of 1:2 to 1:30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227853,"accession_number":"0001493152-24-018497","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra Q1 2024 net loss $2.9M; cash $3.0M; ATR-12/ATR-04 clinical updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss $2.9M vs $2.5M YoY; R&D and G&A each $1.5M vs $0.8M prior year.","Cash and cash equivalents $3.0M as of 3/31/2024; raised $5.0M in Feb 2024 follow-on offering.","ATR-12 Phase 1b trial activated sites, initial patients identified; safety data expected late 2024.","ATR-04 pre-IND meeting completed; IND submission planned mid-2024 for Phase 1b in EGFRi rash.","Bayer joint development agreement progresses; licensing agreement with upfront payment under discussion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246648,"accession_number":"0001493152-24-010097","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra reports FY2023 net loss $11.3M, cash $1.8M; advances ATR-12 Phase 1b and ATR-04 IND","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.3M vs $10.7M in 2022; service revenue from related party $0.7M.","Cash and equivalents $1.8M at Dec 31, 2023, plus $4.4M net from Feb 2024 follow-on.","ATR-12 for Netherton syndrome: Phase 1b trial enrolling ~12 patients; safety data in late 2024.","ATR-04 for EGFRi-associated rash: IND submission mid-2024; first-in-human trial by late 2024/early 2025.","Bayer joint development agreement progressing; expect license agreement with upfront payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246647,"accession_number":"0001493152-24-006365","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Azitra prices $5M public offering of 16.7M shares at $0.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 16,667,000 shares at $0.30/share for gross proceeds of ~$5M.","Underwriters granted 45-day over-allotment option to purchase up to 2.5M additional shares.","Net proceeds to fund clinical trials, R&D, manufacturing, and working capital.","Offering expected to close Feb 16, 2024.","Lock-up agreements for directors and officers until Aug 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264071,"accession_number":"0001493152-23-041260","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra reports Q3 2023 net loss of $1.9M; cash $4.4M; pipeline advances for ATR-12 and ATR-04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.9M narrowed from $2.4M in Q3 2022; R&D expenses fell to $548,524 from $1.4M.","Cash and cash equivalents of $4.4M as of Sept 30, 2023; service revenue from related party of $310,700.","Lead program ATR-12 (Netherton syndrome) IND cleared; CRO hired; first patient enrollment expected in 2024.","ATR-04 (EGFRi-associated rash) advancing toward IND; upcoming milestones include preclinical data and IND submission.","Bayer joint development agreement progressing; royalty-bearing licensing agreement expected as next step."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":596000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281310,"accession_number":"0001493152-23-028459","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azitra reports Q2 2023 net loss of $4.4M; highlights IPO and IND clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M for Q2 2023 vs $1.9M in Q2 2022.","Cash and equivalents $6.3M as of June 30, 2023, including proceeds from $7.5M IPO.","R&D expense fell to $812,836 from $1.5M; G&A rose to $844,640 from $667,940.","Service revenue (related party) $172,000, up from $85,000.","IND cleared for ATR-12 Phase 1b in Netherton syndrome; COO and board appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":285300.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281309,"accession_number":"0001493152-23-024220","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Azitra enters employment agreement with COO Travis Whitfill","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $350,000 per year, subject to annual Board review.","Eligible for annual bonus of 30% of base salary based on performance goals.","If terminated without cause after six months, six-month base salary severance.","Agreement effective July 5, 2023; Mr. Whitfill is a co-founder and current COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281308,"accession_number":"0001493152-23-023980","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Azitra files corporate presentation for non-deal roadshow; no material facts disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company intends to use the presentation in discussions with potential investors during a non-deal roadshow.","No specific financial data, guidance, or operational milestones are reported in the filing.","The presentation content is not summarized; investors would need to review the exhibit directly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300090,"accession_number":"0001493152-23-021998","cik":1701478,"company_name":"Azitra, Inc.","ticker":"AZTR","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["1.01","5.03","7.01","9.01"],"status":"ready","headline":"Azitra completes IPO of 1.5M shares at $5.00; net proceeds ~$6.5M for clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1.5M shares at $5.00/share; gross proceeds $7.5M, net ~$6.5M after expenses.","Underwriters have 45-day option to buy up to 225K additional shares for over-allotments.","Representative's warrants issued for up to 60K shares at $6.25, exercisable Dec 2023 – Jun 2028.","Net proceeds to fund clinical trials, R&D, clinical manufacturing, and general corporate purposes.","Amended and restated certificate of incorporation and bylaws became effective upon closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3421478.658073572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}